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ABSTRACT 
 Background: The objectives of this study were to investigate the predictive 
value of sequential 18F-FDG PET scans for pathological tumor response grade (TRG) 
after preoperative chemoradiotherapy (PCRT) in locally advanced rectal cancer 
(LARC) and the impact of partial volume effects correction (PVC). 
 Methods: 28 LARC patients were included. Responders and nonresponders 
status were determined in histopathology. PET indices (SUV max and mean, volume 
and total lesion glycolysis (TLG)) at baseline and their evolution after one and two 
weeks of PCRT were extracted by delineation of the PET images, with or without 
PVC. Their predictive value was investigated using Mann-Whitney-U tests and ROC 
analysis. 
 Results: Within baseline parameters, only SUVmean was correlated with 
response. No evolution after one week was predictive of the response, whereas after 
two weeks all the parameters except volume were, the best prediction being obtained 
with TLG (AUC 0.79, sensitivity 63%, specificity 92%). PVC had no significant impact 
on these results. 
 Conclusion: Several PET indices at baseline and their evolution after two 
weeks of PCRT are good predictors of response in LARC, with or without PVC, 
whereas results after one week are suboptimal. Best predictor was TLG reduction 
after two weeks, although baseline SUVmean had smaller but similar predictive power. 
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Introduction 
Preoperative radiochemotherapy (PRCT) is now considered a standard treatment for 
patients diagnosed with locally advanced rectal cancer (LARC). A significant tumor 
downsizing and downstaging, as well as a reduction of the risk for local recurrence 
and longer survival have been observed as a result of PRCT (1-3). Within this 
context, 18F-FDG PET imaging has been demonstrated as an interesting predictive 
tool (4). Indeed, correlations between the pathological tumor response after PRCT 
and the SUV decrease within the tumor have been demonstrated in several studies 
(5-9). In most of these studies, the SUV evolution between the baseline PET scan 
and the one acquired before surgery was correlated with the tumor regression grade 
(TRG) (5-9). However, allowing for earlier prediction of the response is of higher 
interest for the clinical practice, since it might enable modifications of the treatment 
protocol (10). A few studies have investigated the early prediction of the pathological 
tumor response based on 18F-FDG PET imaging during PRCT (8-9). Cascini et al. 
showed that changes in the metabolic activity of the tumor, measured as early as 15 
days after the start of PRCT, were predictive for response (8). More recently, 
Janssen et al. have examined three different time points of 18F-FDG PET imaging 
during PRCT, in order to define the optimal time for early prediction (9). In this study 
18F-FDG PET scans at baseline, as well as at 8 and 15 days during PRCT were 
carried out and it was found that the best predictive factor of TRG was the SUVmax 
response index (RI, defined as the percent evolution relative to the pretreatment 
value) at 15 days. All these studies have considered SUV measurements (max 
and/or mean) only. It has been demonstrated recently in several studies and various 
malignancies that other 18F-FDG PET derived parameters more fully characterizing 
tumors on a functional level can have statistically higher predictive value than SUV 
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(10-17). These include metabolically active tumor volume (MATV, defined as the 
tumor volume as it can be seen and delineated on a PET image) (11) and total lesion 
glycolysis (TLG, multiplying MATV and its associated mean SUV) (12). In addition, 
some of these studies demonstrated that response could be predicted by extracting 
these parameters from the pretreatment scan only, therefore potentially eliminating or 
reducing the need for sequential scans during treatment. Such results have been 
presented within the context of locally advanced esophageal cancer (LAEC) (11, 13), 
non-Hodgkin lymphoma (14), pleural mesothelioma (15) and cervix and head & neck 
cancers (16), whereas conflicting results have been recently obtained in rectal cancer 
(17-18). Finally, most of these studies have considered the evolution of PET derived 
parameters without partial volume effects (PVE) correction (PVC). This may lead to 
biased results especially if MATVs change size and/or shape during treatment. The 
current study was therefore conducted retrospectively on the cohort previously 
imaged (9) with the following objectives: 1) determine the predictive value of baseline 
18F-FDG PET derived parameters, 2) investigate the evolution of these parameters 
during treatment and their associated predictive value, and 3) investigate the impact 
of PVC on these results. 
 
MATERIAL AND METHODS 
Patients 
This study consisted of a retrospective analysis of a cohort of 28 patients (see table 
1) diagnosed with nonmetastasized LARC previously recruited in a prospective 
imaging study (9) approved by the medical ethics committee and for which all 
patients gave written informed consent before entering the study. Although all tumors 
may not strictly speaking be considered as locally advanced according to staging, 
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none of the patients could be resected immediately because of the high risks of 
differentiation, bulkiness, and size en location of the tumor. They were therefore all 
treated with the same PCRT protocol as recommended for LARC patients.  All 
patients underwent PRCT (28 fractions of 1.8 Gy, 5 fractions a week, and 
concomitant capecitabine, 825 mg/m2, twice a day), followed by surgery (total 
mesorectal excision). Patients underwent 18F-FDG PET/CT scans at baseline, and on 
days 8 and 15 of treatment. From here onwards, these scans will be denoted as 
PETi, with i from 1 to 3.  
 
18F-FDG PET/CT acquisitions 
The protocol was designed to ensure robust SUV measurements across all three 
time points. Patients received an intravenous injection of FDG after a minimal fasting 
period of 6 hours, with the activity normalized for the weight of the patient as follows: 
(weight [kg] × 4 + 20) [MBq] 
After an uptake period of exactly 60 minutes, all acquisitions were carried out on a 
Siemens Biograph 40 TruePoint scanner (Siemens Medical, Erlangen, Germany) 
with a spatial resolution of approximately 6 mm at full-width-at-half-maximum. 
Listmode data of the abdominal region were acquired in 3D mode with scatter, 
decay, and CT-based attenuation corrections, and 5 min per bed position. Images 
were reconstructed using Fourier rebinning and 2D OSEM (4 iterations, 8 subsets) 
with voxel size 4.1×4.1×3mm3 without post-filtering. 
 
Pathological tumor response grade (TRG) 
The ground-truth of tumor response to therapy was determined in histology since all 
patients underwent total mesorectal excision. As proposed by Mandard et al. (19), 
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TRG for each tumor was determined by an experienced pathologist blinded to the 
imaging data as follows: TRG 1, complete tumor response; TRG 2, residual cancer 
cells scattered through fibrosis; TRG 3, an increased number of residual cancer cells, 
with predominant fibrosis; TRG 4, residual cancer outgrowing fibrosis; and TRG 5, no 
regressive changes within the tumor. Tumors were subsequently grouped into 
responders (TRG 1-2) and nonresponders (TRG 3-5). 
 
Partial volume effects correction 
All PET images were corrected for PVE using an iterative deconvolution method 
previously validated on simulated and clinical datasets (20). This approach iteratively 
estimates the corrected voxels values through Lucy-Richardson deconvolution (21-
22) with prior knowledge (within ±1mm, as it has been shown that a 1mm error in the 
PSF led to a negligible impact on measured SUVs (23)) of the scanner’s Point 
Spread Function (PSF), assumed to  be spatially invariant in the field of view. In this 
study the tumors were all in the exact same body region and this assumption has 
therefore no significant impact on the applied correction on a patient-by-patient 
comparison basis. Wavelet-based denoising was incorporated using Bayeshrink 
filtering (24),  applied to the residual within each iteration of the deconvolution 
process. This allows using a sufficient number of iterations to correct for PVE without 
significant noise addition. This methodology is voxel-based and therefore does not 
assume homogeneous regional radiotracer distributions for the tumor and/or 
surrounding background. 
 
Investigated parameters and analysis 
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All parameters were extracted from the original (PET1-3) and PVE corrected (PET1-
3
PVC) images, denoted from here onwards param1-3 and param1-3
PVC
 respectively. For 
each patient, the tumor was identified on each PETi images by a nuclear physician 
with more than 10 years experience and subsequently semi-automatically isolated 
from the bladder in a 3D region of interest (ROI) using an in-house software. This 
ROI, containing only the MATV and its surrounding background, was automatically 
transferred to the corresponding corrected PETi
PVC image. MATV were subsequently 
delineated on both uncorrected and corrected images using an implementation of the 
Fuzzy Locally Adaptive Bayesian (FLAB) automatic algorithm (25) in the same 
software. The FLAB approach allows automatic tumor delineation by computing a 
probability of belonging to a given “class” (e.g. tumor or background) for each voxel 
within the 3D ROI. This probability is calculated by taking into account the voxel’s 
intensity with respect to the statistical distributions (characterized by their mean and 
variance) of the voxels in the various regions of the image, as well as its spatial 
correlation with neighboring voxels in 3D. This approach has been validated on 
simulated and clinical datasets for accuracy, robustness and reproducibility, on both 
homogeneous and heterogeneous MATVs (25-27). 
SUVmax, and SUVmean as well as the MATV and the TLG were automatically 
calculated from these delineations. MATV was defined as the sum of all voxels 
contained in the FLAB delineated volumes multiplied by the volume of a voxel (50.43 
mm3). TLG was determined by multiplying the MATV and its associated SUVmean. 
Response indices (RIs) corresponding to one (RI2) and two (RI3) weeks were 
calculated as the percentage evolution with respect to the baseline value (PET1) as 
follows: RIn=(paramn-param1)/param1×100 for n=2 and 3. Similarly, RI2-3
PVC were 
calculated using the parameters extracted from PET1-3
PVC images. 
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Figure 1 illustrates for a non responder (fig.1A) and a responder (fig.1B) the baseline 
scan and the scan after 2 weeks, with the delineation of the tumor on both scans. 
 
Statistical analysis 
Statistical analyses were performed using MedcalcTM (MedCalc Software, Belgium). 
All quantitative values were expressed as means ± standard deviations (SD) and 
ranges (minimum - maximum). Binary response status based on TRG classification 
(1-2 vs. 3-5) was correlated with baseline values (param1) as well as RI2-3 for early 
sequential scans (PET2-3) using a Mann-Whitney U test. For the parameters that 
were found to be significantly correlated with response, the predictive performance 
regarding the identification of nonresponders was evaluated using ROC analysis. 
Area under the curve (AUC), along with the best compromise between sensitivity and 
specificity were reported, as well as results associated with a specificity of 100%, 
corresponding to the clinical goal of identifying nonresponders without erroneously 
identifying any of the responders. For RI2-3, only cut-off values above +30% or below 
-30% were considered. This constraint was applied because the reproducibility (or 
test-retest assessment) of the PET derived parameters (both SUV and volume-based 
measurements) under investigation here has been previously determined to be at 
such upper and lower limits (27). Thus characterization of response (or disease 
progression) based on evolution of PET derived indices must take into account such 
reproducibility limits. All tests were two-sided and p values below 0.05 were 
considered statistically significant. 
RESULTS 
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Statistics for baseline and evolution of all derived parameters (with or without PVC) 
are given in table 2. Results of Mann-Whitney U tests and subsequent ROCs 
analyses are provided in the appendix (to be found online, at 
http//www.informahealthcare.com/(DOI number) and table 3 respectively. 
Pathologic tumor response 
6 tumors were characterized by complete pathologic response (TRG 1) and 6 had 
residual cancer cells (TRG 2). 9, 6 and 1 tumors were classified as TRG 3, 4 and 5 
respectively (table 1). There were therefore 12 responders (43%) and 16 
nonresponders (57%). 
Predictive value of baseline parameters 
Without PVC 
Pretreatment SUV measurements were all normally distributed, with SUVmax1 and 
SUVmean1 values for the cohort of 14.9±5.2 and 8.0±2.8 respectively. On the other 
hand, MATV1 and TLG1 were not normally distributed. Median MATV1 and TLG1 
values were 23cm3 and 181g respectively. Most volumes were within the range of 10 
to 40 cm3, with 5 tumors above 100 cm3. 
Responding tumors were characterized by higher baseline SUV (SUVmax1 15.6±3.7 
and SUVmean 9.0±2.3) than nonresponding ones (SUVmax1 12.5±5.8 and SUVmean 
6.4±2.9). The difference was not significant for SUVmax (p=0.06) contrary to SUVmean 
(p=0.02), with an associated AUC of 0.75 (table 3) leading to perfect specificity 
(100%) but an associated sensitivity of 50% for a cut-off value of 6.1. 
No correlation between response and MATV1 or TLG1 was found (p>0.1), 
distributions of these parameters among responders and nonresponders being 
largely overlapped (table 2). 
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With PVC 
Pretreatment SUVmax and SUVmean increased by +57±23% and +27±10% after 
correction, to 21.2±9.7 and 10.2±4.0 respectively. On the other hand, MATV1
PVC were 
systematically smaller with however a small difference of only -12±6% (range -3% to 
-24%). Resulting from a combination of smaller MATV and higher SUVmean, TLG1
PVC 
increased by +11±7% (range -1% to +31%). The increase of SUVmean was strongly 
correlated with MATV (r>0.7, p<0.0001) whereas increase of SUVmax was not (r<0.5). 
Despite these absolute values increase, the differences between responding and 
nonresponding tumors were not significantly altered by PVC. SUVmax1
PVC still did not 
significantly separate responding from nonresponding tumors (p=0.07) whereas 
SUVmean1
PVC
 allowed similar differentiation (p=0.02), and no correlation with response 
was found for MATV1
PVC and TLG1
PVC (p>0.2). 
Regarding ROC analysis, AUCs and associated optimal sensitivities/specificities with 
PVC were mostly similar as without correction. For SUVmean1
PVC, AUC increased from 
0.75 to 0.76, although it led to a reduced sensitivity (44% instead of 50%) with the 
same specificity of 100% (figure 2A). 
 
Evolution of parameters during PRCT and associated predictive value 
Without PVC 
There was a global trend to decreasing MATV and associated uptake of the tumors 
during PRCT across the cohort of patients, with further reduction at 15 days (table 2). 
However, these PET parameters were also found to be increasing for some patients 
(table 2), especially after 8 days. The lowest decreases at 8 days were observed for 
MATV and SUVmax (mean -12% and -15%, median -18% for both) whereas the 
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largest decrease was observed for TLG with a mean of -22% (median -35%). 
Decrease was systematically larger at 15 days, with for instance -48 mean TLG 
decrease (median -57%). 
On the one hand, none of the RI2s were statistically different between responders 
and nonresponders, except for SUVmean (-6±44% vs. -25±12%, p=0.04) and TLG (-
18±53% vs. -37±15%, p=0.03). On the other hand, RI3s of all the parameters except 
MATV were statistically different between responders and nonresponders, especially 
for TLG and SUVmean (p=0.009). 
According to ROCs analysis, RI2s of neither SUVmean nor TLG (the only two 
parameters for which there was a statistical difference at 8 days between responders 
and nonresponders) allowed satisfactory prediction of TRG. With an AUC of 0.73, the 
optimal cut-off value above 30% change (-31%) for SUVmean was associated with a 
sensitivity of 88% but a specificity of only 33%. RI2 of TLG led to an AUC of 0.75 and 
much lower sensitivity (56%) but higher specificity (67%) with a cut-off value of -34%. 
At 8 days, 100% specificity could be achieved only using too low cut-off values (-10% 
only for SUVmean, and -23% for TLG) and at the cost of reduced sensitivity for 
SUVmean (50%). 
Predictive performance improved at 15 days with higher sensitivities/specificities for 
all parameters. For SUVmax, a -43% RI3 cut-off value was associated with 88% 
sensitivity and 58% specificity, whereas a -34% RI3 for SUVmean led to 81% sensitivity 
and 67% specificity. Reduction of TLG using a RI3 cut-off value of -53% led to lower 
sensitivity (63%) but higher specificity (92%) (figure 2B). At 15 days, maximizing 
specificity was associated with low RI3 cut-off values (-11 and -16% for SUVmean and 
SUVmax), except for TLG for which the cut-off value was -37%, with however a 
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sensitivity of only 38%. Sensitivities associated with 100% specificity were also 
between 30 and 40% for the other parameters. 
 
With PVC 
Evolution of the parameters after 8 and 15 days was not significantly altered by PVC, 
with very similar values of RIs for all parameters (see table 2). PVC had therefore no 
impact on the statistical difference between RIs of responders and nonresponders. 
After correction, the RI2s still did not allow statistical differentiation between 
responders and nonresponders for most parameters, except for TLG and SUVmean 
which was already the case without PVC. Similarly, all the RI3s except MATV were 
still able to statistically differentiate the nonresponders from the responders after 
PVC, but the differentiation was significantly neither improved nor reduced. 
Similarly, ROCs results were not significantly altered by PVC, although AUCs varied 
by up to ±0.05. Sensitivities and specificities corresponding to optimal cut-off values 
on the other hand were in a few cases significantly modified. For example, the 
sensitivity associated with RI3 of SUVmax was decreased after PVC from 88 to 50%, 
with an increase of specificity from 58 to 83%. Similar changes were observed for the 
other parameters at both 8 and 15 days, without nonetheless significantly reduce or 
increase the predictive performance of the parameters. 
DISCUSSION 
Neither the predictive value of baseline PET images nor the one of PET features 
more fully describing tumors (MATV, TLG) has been extensively determined yet 
within the context of PCRT early prediction in rectal cancer. Melton and colleagues 
found in 21 LARC patients that the reduction of PET-based parameters (MATV, TLG 
and SUV) between baseline and 4-6 weeks after treatment was correlated with 
 13 
pathological response (17), but they did not investigate the value of baseline 
parameters. More recently, Chennupati and colleagues did not find a correlation 
between pathological response and SUVmax or MATV measurements at baseline or 
reduction after treatment in a cohort of 35 LARC patients, but they did not investigate 
the value of parameters reduction during the treatment (18). Janssen and colleagues 
demonstrated that the reduction of SUVmax after 2 weeks was a good predictor of 
response, but they did not investigate other PET parameters beyond SUVmean or their 
baseline predictive value (9). None of these studies investigated the impact of PVC. 
To the best of our knowledge, the current study is the first investigation on a 
homogeneous LARC cohort including the impact of PVC, four PET derived 
parameters (SUVmax, SUVmean, MATV, TLG), and three (baseline and after 1 and 2 
weeks) 18F-FDG PET scans during PCRT.  
 
On the one hand, contrary to results in LAEC (10), neither the baseline MATV nor the 
derived TLG were significantly associated with response. On the other hand, some of 
the baseline parameters were of predictive value, such as higher SUVmean being 
associated with responding tumors (p=0.02), and allowed prediction of the 
nonresponders with a specificity of 100% but a limited sensitivity of 50%. A similar 
trend was observed with SUVmax, although without reaching statistical significance 
(p=0.06). 
 
Overall, response was associated with higher decrease of the 18F-FDG PET derived 
indices within the first two weeks of PCRT, especially SUVmean and TLG (p<0.01), 
although this decrease was a more efficient predictive factor after two weeks than 
one, in line with previous findings (9). First, none of the parameters' RI2s except for 
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SUVmean and TLG were significantly correlated with TRG. Second, an important 
constraint was that cut-off values of RI2-3s had to be larger than ±30%, because of the 
upper and lower reproducibility limits of such PET derived measurements (27). 
However, measured RI2-3s were often within this range, especially after one week, 
although it was still the case even after two weeks. This may constitutes one of the 
major limitations of early PET based response prediction, and the reproducibility of 
PET acquisitions clearly need to be improved in that regard. On the one hand, 
according to ROCs analysis, the reduction of SUVmean after 2 weeks was associated 
with an AUC of 0.79, a 100% specificity and 31% sensitivity associated with a RI2 
cut-off value of -11%, which is too low with regard to the reproducibility limits, as it is 
the case for all other parameters. The only exception was TLG: a -37% RI3 cut-off 
value led to 100% specificity and 38% sensitivity, whereas a -53% cut-off value led to 
the best compromise of 63% sensitivity and 92% specificity. 
 
Usually, higher SUVs are associated with more aggressive tumors, and therefore 
may be potentially more resistant. However according to our results, responding 
tumors were found to have higher initial SUVs. This can be associated with the fact 
that they were also the ones exhibiting the highest uptake decrease during treatment. 
In addition, the tumors that were classified as nonresponders based on the RI3 of 
TLG (specificity 100%, sensitivity 38%) are almost the same as those classified as 
nonresponders based on their baseline mean SUVs (specificity 100%, sensitivity 
50%). Therefore waiting for 2 weeks did not significantly (p>0.05) improve prediction 
of response in this context when maximizing specificity, despite increased overall 
AUCs, which is a new result with respect to previous findings that only investigated 
the predictive value of RIs and not absolute baseline values (9). 
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The classification could be further improved using logistic regression of several 
parameters such as baseline MATV and SUVmean values and their evolution at 8 and 
15 days, resulting in an AUC of 0.88, with a sensitivity and specificity of 88% and 
83% respectively, whereas a specificity of 100% was associated with 50% sensitivity 
(figure 2C). Similar results were obtained with PVC (AUC 0.92, 92% specificity and 
81% sensitivity, 56% sensitivity associated with 100% specificity). However, such 
weighted model combining more than one parameter on 28 patients only is likely to 
be over fitted to the data and would require validation on a larger cohort. 
 
Regarding PVC, despite significant impact on the absolute values (except for MATV), 
it had limited impact on the predictive value of the parameters. Similar results 
regarding the impact of PVC on baseline predictive value were obtained for baseline 
prediction of chemoradiotherapy response in LAEC (28). This is the first study 
however investigating the PVC impact on the predictive value of sequential scans. 
This lack of impact may be explained by the fact that although the tumor volumes 
significantly shrinked during the first two weeks of PCRT (-36±29% after 2 weeks), 
their volume were still large (mean 36cm3). Since PVE are significant for volumes 
below 10-15 cm3, PVC impact should be investigated for the follow-up of tumors 
exhibiting larger changes and/or smaller volumes. 
Some limits of this study have to be emphasized. It is first limited by its retrospective 
nature and the small number of patients, which led to group the five different 
classifications of TRG into responders and nonresponders. Investigation of other 
response classification such as complete regression (TRG1) vs. non-response (TRG 
2-5) or all five TRG statuses should be conducted in larger prospective studies in 
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order to validate our preliminary results. Finally, the TRG classification, although it 
constitutes the best measurement of tumor response available, was determined by 
one pathologist only. 
CONCLUSION 
Our results in this preliminary study suggest that early prediction of tumor 
response to PRCT in rectal cancer using sequential 18F-FDG PET scans is 
challenging due to limited reproducibility of PET imaging, especially after one week 
that was found to be suboptimal in both robustness due to small evolutions of the 
parameters and accuracy with no correlation with response. The best compromise 
between accuracy and robustness of prediction was obtained by considering the 
reduction of total lesion glycolysis after two weeks of PCRT, with a sensitivity of 63% 
and specificity of 92%, although the improvement over baseline absolute mean SUV 
prediction (specificity 100%, sensitivity 50%) was not significant. Finally, partial 
volume effects correction had no impact on the predictive value of neither the 
baseline absolute values nor their evolution during treatment. The results of this 
study require validation in a larger cohort allowing consideration of less restrictive 
response measures. 
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Table captions 
Table 1: patients characteristics. 
Table 2: baseline values and evolution (RIs) of each PET derived parameter with 
respect to baseline values 
Table 3: predictive value of each parameter baseline values and RIs using ROCs 
analysis. Only parameters for which a significant correlation was found (see 
appendix, to be found online, at http//www.informahealthcare.com/(DOI number)) are 
included. 
 
Figure captions 
Figure 1: Illustration of the baseline scan (on the left) and the scan at 2 weeks 
(PET3, on the right) for (A) a responder and (B) a non responder. The green contour 
is the FLAB delineation. 
Figure 2: ROCs examples for prediction of nonresponders (n=16), using (A) SUVmean 
with or without PVC, (B) TLG and SUVmean RI3, and (C) logistic regression combining 
baseline MATV and SUVmean values and their evolution after 8 and 15 days, with and 
without PVC. 
 
Appendix: correlation between TRG (nonresponders as TRG 3-5 and responders as 
TRG 1-2) and baseline values as well as RIs, for each PET derived parameter, with 
and without PVC.  
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Parameter Number of patients (%) 
Gender  
  Male 18(64) 
  Female  10(36) 
 
Age  
  Range 44-81 
  Median 67 
 
TNM Stage  
           T1 0(0) 
           T2 1(4) 
           T3 24(85) 
           T4 3(11) 
  
           N0 4(14) 
           N1 8(29) 
             N2 16(57) 
  
           M0 28(100) 
           M1 0(0) 
  
TRG status  
           1 6(21) 
           2 6(21) 
           3 9(33) 
           4 6(21) 
           5 1(4) 
 
Table I 
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Parameter 
Baseline value median±SD 
(mean, min, max) 
RI2 (%) median±SD 
(mean, min, max) 
RI3 (%) median±SD 
(mean, min, max) 
SUVmax
 13.9±5.2 (14.9, 6.6, 26.7) -18±39 (-12, -63, +155) -32±25 (-31, -73, +47) 
SUVmax
PVC 21.2±9.7 (23.8, 10.2, 49.3) -20±41 (-15, -59, +165) -43±27 (-38, -75, +47) 
SUVmean 7.8±2.8 (8.0, 3.7, 13.9) -20±36 (-11, -59, +138) -29±25 (-28, -66, +54) 
SUVmean
PVC 10.2±4.0 (10.3, 4.5, 20.8) -22±37 (-12, -56, +153) -28±24 (-29, -67, +42) 
MATV  23±79 (49, 2, 397) -18±22 (-15, -51, +51) -36±29 (-32, -80, +42) 
MATVPVC 19±76 (45, 2, 378) -15±22 (-15, -51, +39) -32±28 (-32, -78, +37) 
TLG 181±473 (345, 10, 2235) -35±45 (-22, -75,+137) -57±37 (-48, -86, +68) 
TLGPVC 196±518 (379, 13, 2385) -34±41 (-24, -75, +130) -59±33 (-50, -88, +51) 
 
Table II 
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Parameter* AUC 
Cut-off 
value 
Sensitivity 
(%) 
Specificity 
(%) 
Sensitivity 
for 100% 
specificity 
(%) 
Cut-off 
value 
SUVmax RI3 (%) 0.77 -43 88 58 31 -16 
SUVmax
PVC RI3 (%) 0.73 -33 50 83 13 -5 
SUVmean 
PET1 0.75 6.1 50 100 50 6.1 
RI2 (%) 0.73 -31 88 33 50 -10 
RI3 (%) 0.79 -34 81 67 31 -11 
SUVmean
PVC 
PET1 0.76 7.3 44 100 44 7.3 
RI2 (%) 0.77 -33 81 25 50 -8 
RI3 (%) 0.75 -42 88 58 19 -8 
TLG 
RI2 (%) 0.75 -34 56 67 56 -23 
RI3 (%) 0.79 -53 63 92 38 -37 
TLGPVC 
RI2 (%) 0.70 -34 56 50 44 -18 
RI3 (%) 0.78 -54 63 92 31 -38 
 
Table 3 
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Figure 1 
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Figure 2A 
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Figure 2B 
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Figure 2C 
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Appendix 
Parameter 
median±SD 
Nonresponders 
(n=16) 
Responders 
(n=12) 
p  
SUVmax 
PET1 12.5±5.8 15.6±3.7 0.06 
RI2 (%) -9±32 -24±19 0.09 
RI3 (%) -24±28 -44±21 0.01 
SUVmax
PVC 
PET1
PVC 20.3±10.5 25.8±7.7 0.07 
RI2
PVC (%) -15±36 -31±20 0.1 
RI3
 PVC
 (%) -30±31 -48±24 0.04 
SUVmean 
PET1 6.4±2.9 9±2.3 0.02 
RI2 (%) -6±44 -25±12 0.04 
RI3 (%) -24±25 -42±17 0.009 
SUVmean
PVC 
PET1
PVC 8±3.7 11.0±3.8 0.02 
RI2
PVC (%) -7±46 -25±11 0.02 
RI3
 PVC
 (%) -24±24 -43±20 0.03 
MATV 
PET1 (cm
3) 26±100 16±26 0.2 
RI2 (%) -14±27 -20±15 0.3 
RI3 (%) -33±33 -45±18 0.08 
MATVPVC 
PET1
PVC (cm3) 21±96 14±24 0.2 
RI2
PVC (%) -15±25 -17±18 0.5 
RI3
 PVC
 (%) -28±31 -45±19 0.1 
TLG 
PET1 (g) 225±594 165±227 0.6 
RI2 (%) -18±53 -37±15 0.03 
RI3 (%) -46±43 -67±14 0.009 
TLGPVC 
PET1
PVC (g) 246±653 178±236 0.7 
RI2
PVC (%) -21±49 -37±16 0.05 
RI3
 PVC
 (%) -46±38 -67±14 0.01 
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